BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

774 related articles for article (PubMed ID: 18343771)

  • 1. [Cytomegalovirus infection after solid-organ transplantation, its risk factors, direct and indirect effects and prevention strategies].
    Varga M; Remport A; Czebe K; Péter A; Toronyi E; Sárváry E; Fehérvári I; Sulyok B; Járay J
    Orv Hetil; 2008 Mar; 149(12):551-8. PubMed ID: 18343771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of the prevention strategies on the indirect effects of CMV infection in solid organ transplant recipients.
    Roman A; Manito N; Campistol JM; Cuervas-Mons V; Almenar L; Arias M; Casafont F; del Castillo D; Crespo-Leiro MG; Delgado JF; Herrero JI; Jara P; Morales JM; Navarro M; Oppenheimer F; Prieto M; Pulpón LA; Rimola A; Serón D; Ussetti P;
    Transplant Rev (Orlando); 2014 Apr; 28(2):84-91. PubMed ID: 24602805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Viral load, CMV-specific T-cell immune response and cytomegalovirus disease in solid organ transplant recipients at higher risk for cytomegalovirus infection during preemptive therapy.
    Martín-Gandul C; Pérez-Romero P; Blanco-Lobo P; Benmarzouk-Hidalgo OJ; Sánchez M; Gentil MA; Bernal C; Sobrino JM; Rodríguez-Hernández MJ; Cordero E;
    Transpl Int; 2014 Oct; 27(10):1060-8. PubMed ID: 24964364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of cytomegalovirus disease in solid organ transplant patients: prophylactic versus preemptive therapy.
    Baillie GM
    Am J Health Syst Pharm; 2006 Oct; 63(19 Suppl 5):S10-6. PubMed ID: 16990639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytomegalovirus in transplantation - challenging the status quo.
    Fishman JA; Emery V; Freeman R; Pascual M; Rostaing L; Schlitt HJ; Sgarabotto D; Torre-Cisneros J; Uknis ME
    Clin Transplant; 2007; 21(2):149-58. PubMed ID: 17425738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytomegalovirus infection post-pancreas-kidney transplantation--results of antiviral prophylaxis in high-risk patients.
    Fallatah SM; Marquez MA; Bazerbachi F; Schiff JR; Cattral MS; McGilvray ID; Norgate A; Selzner M; Rotstein C; Husain S
    Clin Transplant; 2013; 27(4):503-9. PubMed ID: 23731387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preventing post-organ transplantation cytomegalovirus disease with ganciclovir: a meta-analysis comparing prophylactic and preemptive therapies.
    Small LN; Lau J; Snydman DR
    Clin Infect Dis; 2006 Oct; 43(7):869-80. PubMed ID: 16941368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preemptive anti-cytomegalovirus therapy in high-risk (donor-positive, recipient-negative cytomegalovirus serostatus) kidney transplant recipients.
    Hasegawa J; Hatakeyama S; Wakai S; Omoto K; Okumi M; Tanabe K; Mieno M; Shirakawa H
    Int J Infect Dis; 2017 Dec; 65():50-56. PubMed ID: 28986314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytomegalovirus infection and disease in the new era of immunosuppression following solid organ transplantation.
    Fisher RA
    Transpl Infect Dis; 2009 Jun; 11(3):195-202. PubMed ID: 19228345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytomegalovirus infection in organ transplant recipients.
    Hibberd PL; Snydman DR
    Infect Dis Clin North Am; 1995 Dec; 9(4):863-77. PubMed ID: 8747770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytomegalovirus infection after liver transplantation: current concepts and challenges.
    Razonable RR
    World J Gastroenterol; 2008 Aug; 14(31):4849-60. PubMed ID: 18756591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention strategies for cytomegalovirus disease and long-term outcomes in the high-risk transplant patient (D+/R-): experience from the RESITRA-REIPI cohort.
    Meije Y; Fortún J; Len Ó; Aguado JM; Moreno A; Cisneros JM; Gurguí M; Carratalà J; Muñoz P; Montejo M; Blanes M; Bou G; Pérez JL; Torre-Cisneros J; Ramos A; Pahissa A; Gavaldà J;
    Transpl Infect Dis; 2014 Jun; 16(3):387-96. PubMed ID: 24807640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Post-renal transplant cytomegalovirus infection: study of risk factors.
    Kute VB; Vanikar AV; Shah PR; Gumber MR; Patel HV; Godara SM; Munjappa BC; Sainaresh VV; Engineer DP; Jain SH; Modi PR; Shah VR; Trivedi VB; Trivedi HL
    Transplant Proc; 2012 Apr; 44(3):706-9. PubMed ID: 22483473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir.
    Razonable RR; Rivero A; Rodriguez A; Wilson J; Daniels J; Jenkins G; Larson T; Hellinger WC; Spivey JR; Paya CV
    J Infect Dis; 2001 Dec; 184(11):1461-4. PubMed ID: 11709790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytomegalovirus risk factors in renal transplantation with modern immunosuppression.
    Bataille S; Moal V; Gaudart J; Indreies M; Purgus R; Dussol B; Zandotti C; Berland Y; Vacher-Coponat H
    Transpl Infect Dis; 2010 Dec; 12(6):480-8. PubMed ID: 20629971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients.
    Kalil AC; Levitsky J; Lyden E; Stoner J; Freifeld AG
    Ann Intern Med; 2005 Dec; 143(12):870-80. PubMed ID: 16365468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improving outcomes for solid-organ transplant recipients at risk from cytomegalovirus infection: late-onset disease and indirect consequences.
    Legendre C; Pascual M
    Clin Infect Dis; 2008 Mar; 46(5):732-40. PubMed ID: 18220478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preemptive therapy versus valgancyclovir prophylaxis in cytomegalovirus-positive kidney transplant recipients receiving antithymocyte globulin induction.
    Couzi L; Helou S; Bachelet T; Martin S; Moreau K; Morel D; Lafon ME; Garrigue I; Merville P
    Transplant Proc; 2012 Nov; 44(9):2809-13. PubMed ID: 23146529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A risk-stratified approach to cytomegalovirus prevention in pediatric solid organ transplant recipients.
    Suresh S; Lee BE; Robinson JL; Akinwumi MS; Preiksaitis JK
    Pediatr Transplant; 2016 Nov; 20(7):970-980. PubMed ID: 27565955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The case for cytomegalovirus prophylaxis in solid organ transplantation.
    Snydman DR
    Rev Med Virol; 2006; 16(5):289-95. PubMed ID: 16888821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.